Browsing Category
Pharma Industry News
4721 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
What NPX-5’s Phase IIb trial means for the future of oncology-linked mental health treatments
NPX-5 enters Phase IIb trials for cancer-related mental health. Discover what this means for biotech strategy, regulation, and future treatments.
Can RNA-based cancer vaccines finally close the HRP ovarian cancer treatment gap?
Can RNA cancer vaccines close the ovarian cancer gap? Explore Epitopea’s strategy, risks, and what investors should watch next.
Moderna faces fresh mRNA patent assault from CureVac as BioNTech tightens legal grip on COVID-19 vaccine royalties
Moderna just settled $950 million in mRNA litigation. Now BioNTech-owned CureVac wants Spikevax royalties too. The patent war is widening.
What clinicians and regulators will watch next after neflamapimod’s MRI results
CervoMed Inc. (NASDAQ: CRVO) reveals neflamapimod MRI data. Discover what clinicians and regulators will watch next in DLB trials.
Is TPST-2003’s early efficacy enough to disrupt the current CAR-T landscape in multiple myeloma
Can TPST-2003 disrupt CAR-T therapy in multiple myeloma? Explore what Tempest Therapeutics, Inc.’s strategy means for investors and the industry.
Why anti-CD20 competition in multiple sclerosis is shifting toward real-world performance data
Discover why real-world data is reshaping anti-CD20 competition in MS and what it means for TG Therapeutics, Inc.’s BRIUMVI strategy. Read more.
What rezanecel’s durability data means for epilepsy treatment innovation
Neurona Therapeutics’ rezanecel shows durable seizure reduction. Discover what this means for epilepsy treatment innovation and future market dynamics.
Eli Lilly (NYSE: LLY) bets on oral GLP-1 Foundayo and retatrutide to reclaim its $1tn valuation
Eli Lilly (NYSE: LLY) launched Foundayo, the world's first oral GLP-1 for obesity, in April 2026 and reports Q1 earnings April 30. Full pipeline and risk analysis for retail investors.
Gujarat Themis Biosyn (GUJTHEM) bets on global branded generics with €158m Sanofi portfolio deal
Find out how Gujarat Themis Biosyn’s €158m Sanofi portfolio deal could reshape its global anti-infective growth strategy.
LABT lists on Nasdaq: Can Lakewood-Amedex Biotherapeutics’ Bisphosphocin class crack antibiotic resistance?
Lakewood-Amedex Biotherapeutics (LABT) lists on Nasdaq with Nu-3 antimicrobial targeting infected diabetic foot ulcers. Read what it means for AMR investors.